We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order
Read MoreHide Full Article
The index traversed yet another volatile week but still managed to notch up strong gains. The Federal Reserve hinted that it was unlikely to announce any rate hike this year, following signs of economic weakness. But investors remained concerned over the lack of clarity on the status of trade talks. Sharp movements from shares of Apple (AAPL - Free Report) and Boeing (BA - Free Report) largely determined the direction of the index.
Last Week’s Performance
The index gained 0.5% last Friday as optimism around a U.S.-China trade deal boosted investor sentiment. Further, China’s pledge to counter its economic woes also boosted indices. Gains for the 30-stock index were buoyed by a 1.5% surge in the shares of Boeing after reports surfaced that the aerospace giant was planning to initiate a software upgrade for its 737 Max model.
The index increased 1.6% over last week. This was the Dow’s best weekly gain since Feb 15. Meanwhile, the UK parliament voted against a no-deal Brexit and President Donald Trump said that he was ready to give more time for a trade deal with China.
In other news, Fed chair Jerome Powell remained bullish about the U.S. economy. On Mar 10, in an interview with “60 Minutes”, Fed chairman Jerome Powell said that the U.S. economy will continue to grow in 2019 albeit at a slower pace.
However, investors remained anxious about the delay in sealing a U.S.-China trade deal. Moreover, weak earnings data from the United States and China also dented investors’ confidence.
The DowThisWeek
The index increased 0.5% on Monday ahead of the Federal Reserve’s two-day policy meeting. The Dow registered its fourth consecutive close in the green. Meanwhile, federal prosecutors began scrutinizing the development of Boeing’s MAX 737 jetliner.
The Dow also posted its best close since Mar 1. Gains for the 30-stock index were buoyed by a 1% rise in the shares of Apple. However, gains for the index were capped by steep losses for Boeing.
The index lost 0.1% on Tuesday after reports surfaced that trade talks between the United States and China had hit a rough patch. Following this, the three major benchmarks pared early gains. Shares of Apple declined 0.9% and were the biggest drag on the 30-stock index.
The index lost 0.6% on Wednesday following a decline in bank stocks after the Fed indicated that further rate hikes in 2019 were largely unlikely. Following the central bank’s statement, yields on various government bonds took a nosedive. Moreover, conflicting news from the trade war front also dampened investors’ spirits.
The index gained 0.8% on Thursday, enjoying its best daily gain since Feb 15. Stocks were propelled higher after the Fed hinted earlier this week that it was unlikely to raise rates this year. Gains for the index were powered by shares of Apple which gained 3.7% after being upgraded by Needham.
Components Moving the Index
Apple updated its iPad and iMac devices, prior to the much-anticipated Mar 25 event, where the iPhone-maker is set to launch video streaming and news subscription services.
The new ultra-thin iPad Air measures 10.5 inches diagonally and is supported by Apple Pencil. Moreover, iPad Air performance is expected to be 70% better, due to the A12 Bionic chip and Apple’s Neural Engine.
Zacks Rank #3 (Hold) Apple also launched the new 7.9-inch iPad mini that delivers “three times the performance and nine times faster graphics.” The device is 25% brighter and has the highest pixel density among any of the iPads, powered by the advanced Retina display with True Tone technology.
Exxon Mobil Corporation (XOM - Free Report) and TOTAL SA have reached an agreement related to increased gas exports from Papua New Guinea (PNG).
Per the plan, the capacity of Zacks Rank #3 ExxonMobil-operated PNG liquefied natural gas (LNG) plant will be increased to around 16 million tons per annum (mtpa) from its current capacity of 6.9 mtpa. According to analysts, the move will enable the company to compete with Australia’s biggest LNG projects.
The cost of the expansion is valued at about $13 billion, lower than the initial cost projection of $19.5 billion. The cost per ton is less than 50% from Chevron Corp’s (CVX - Free Report) Gorgon LNG plant in Australia.
The expansion will include the addition of three new LNG trains with a capacity of 2.7 mtpa each on the existing PNG LNG plant site. Two of these trains will be supported by gas from the Elk-Antelope fields, which is managed by TOTAL. (Read: ExxonMobil to Increase Export From PNG LNG Plant)
Boeing recently won a $327 million contract to upgrade the P-8A aircraft. The contract was awarded by the Naval Air Systems Command, Patuxent River, Maryland.
Per the terms of the deal, the aerospace giant will develop, integrate and test Increment 3 Block capabilities into the P-8A aircraft for the Navy and the government of Australia. Majority of the work related to the deal will be performed in Puget Sound, WA. The entire task related to the deal is expected to be completed by March 2024.
Boeing will utilize fiscal 2019 research, development, test and evaluation (Navy) funds and Cooperative Engagement Agreement funds for completing the task. The stock has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Goldman Sachs (GS - Free Report) , through its subsidiary Goldman Sachs Asset Management ("GSAM"), has agreed to acquire Standard & Poor's Investment Advisory Services LLC ("SPIAS"), a wholly owned subsidiary of S&P Global (SPGI - Free Report) . The deal is expected to close in the first half of 2019.
SPIAS manages portfolios using Exchange Traded Funds (“ETFs”) and mutual funds, as well as equity portfolios produced employing a rules-based investment process. It is a provider of non-discretionary advisory services to institutional clients on a global level.
As of Dec 31, 2018, it advised on more than $33 billion in assets across multi-asset, equity, and fixed income strategies.
Zacks Rank #4 (Sell) Goldman’s ETFs sales are likely to get a boost from this acquisition, which will expand the unit’s multi-asset offerings and rules-based equity strategies. The expansion is in sync with the growing demands of customers. (Read: Goldman Sachs to Acquire S&P's Investment Advisory Services)
Pfizer, Inc. (PFE - Free Report) and partner Merck KGaA announced the discontinuation of a late-stage study evaluating a combination of its PD-L1 inhibitor, Bavencio and its new PARP inhibitor, Talzenna (talazoparib) for first-line ovarian cancer. Pfizer has a Zacks Rank #4.
The phase III JAVELIN Ovarian PARP 100 study (n=998) evaluated Bavencio (avelumab) + chemotherapy followed by a maintenance treatment of avelumab + Talzenna versus an active comparator for previously untreated advanced ovarian cancer.
The companies said several factors led to the decision to end the JAVELIN Ovarian PARP 100 study, which did not include safety reasons. First, the degree of benefit observed with avelumab in frontline ovarian cancer in the JAVELIN Ovarian 100 study did not support continuation of the JAVELIN Ovarian PARP 100 study, the companies said or for that matter evaluating an immunotherapy in ovarian cancer itself.
Also, the approval of AstraZeneca/Merck’s PARP inhibitor, Lynparza in the first-line maintenance setting for ovarian cancer in December last year has raised competitive pressure in the PARP inhibitor market. (Read: Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study)
JPMorgan Chase (JPM - Free Report) has started offering low-fee checkless accounts. The new account, called Secure, does not require any minimum balance and has access to the company’s mobile app, branches and ATMs for $4.95 a month. The news was first reported by Reuters. JPMorgan has a Zacks Rank #4.
These accounts are no-overdraft accounts but come with debit cards, digital payments and free check cashing. Moreover, these accounts charge $60 annually, which is significantly below the charge of $200-$500 per annum at check cashing and money order services. (Read: JPMorgan Offers Checkless Accounts for Low-Income Customers)
Performance of the Top 10 Dow Companies
The table given below shows the price movements of the 10 largest components of the Dow, which is a price-weighted index, over the last five days and during the last six months. Over the last five trading days, the Dow has gained 0.6%.
Next Week’s Outlook
Boeing’s woes are far from over and will continue to trouble the Dow for some time to come. However, the stock’s fundamentals are in place and such volatility could be short term at best. Further, investors will be relieved that a rate hike has been more or less been ruled out for the year.
However, concerns over trade negotiations continue to linger and will likely keep investors guessing next week. If crucial economic data, such as upcoming GDP numbers are encouraging, stocks could receive the impetus required for steady gains in the days ahead.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%,+119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Dow 30 Stock Roundup: AAPL Refreshes Product Lineup, BA Wins $327M Navy Order
The index traversed yet another volatile week but still managed to notch up strong gains. The Federal Reserve hinted that it was unlikely to announce any rate hike this year, following signs of economic weakness. But investors remained concerned over the lack of clarity on the status of trade talks. Sharp movements from shares of Apple (AAPL - Free Report) and Boeing (BA - Free Report) largely determined the direction of the index.
Last Week’s Performance
The index gained 0.5% last Friday as optimism around a U.S.-China trade deal boosted investor sentiment. Further, China’s pledge to counter its economic woes also boosted indices. Gains for the 30-stock index were buoyed by a 1.5% surge in the shares of Boeing after reports surfaced that the aerospace giant was planning to initiate a software upgrade for its 737 Max model.
The index increased 1.6% over last week. This was the Dow’s best weekly gain since Feb 15. Meanwhile, the UK parliament voted against a no-deal Brexit and President Donald Trump said that he was ready to give more time for a trade deal with China.
In other news, Fed chair Jerome Powell remained bullish about the U.S. economy. On Mar 10, in an interview with “60 Minutes”, Fed chairman Jerome Powell said that the U.S. economy will continue to grow in 2019 albeit at a slower pace.
However, investors remained anxious about the delay in sealing a U.S.-China trade deal. Moreover, weak earnings data from the United States and China also dented investors’ confidence.
The Dow This Week
The index increased 0.5% on Monday ahead of the Federal Reserve’s two-day policy meeting. The Dow registered its fourth consecutive close in the green. Meanwhile, federal prosecutors began scrutinizing the development of Boeing’s MAX 737 jetliner.
The Dow also posted its best close since Mar 1. Gains for the 30-stock index were buoyed by a 1% rise in the shares of Apple. However, gains for the index were capped by steep losses for Boeing.
The index lost 0.1% on Tuesday after reports surfaced that trade talks between the United States and China had hit a rough patch. Following this, the three major benchmarks pared early gains. Shares of Apple declined 0.9% and were the biggest drag on the 30-stock index.
The index lost 0.6% on Wednesday following a decline in bank stocks after the Fed indicated that further rate hikes in 2019 were largely unlikely. Following the central bank’s statement, yields on various government bonds took a nosedive. Moreover, conflicting news from the trade war front also dampened investors’ spirits.
The index gained 0.8% on Thursday, enjoying its best daily gain since Feb 15. Stocks were propelled higher after the Fed hinted earlier this week that it was unlikely to raise rates this year. Gains for the index were powered by shares of Apple which gained 3.7% after being upgraded by Needham.
Components Moving the Index
Apple updated its iPad and iMac devices, prior to the much-anticipated Mar 25 event, where the iPhone-maker is set to launch video streaming and news subscription services.
The new ultra-thin iPad Air measures 10.5 inches diagonally and is supported by Apple Pencil. Moreover, iPad Air performance is expected to be 70% better, due to the A12 Bionic chip and Apple’s Neural Engine.
Zacks Rank #3 (Hold) Apple also launched the new 7.9-inch iPad mini that delivers “three times the performance and nine times faster graphics.” The device is 25% brighter and has the highest pixel density among any of the iPads, powered by the advanced Retina display with True Tone technology.
The new iMac features Intel’s (INTC - Free Report) 8-core 9th-generation processors and Radeon Pro Vega graphics from Advanced Micro Devices (AMD - Free Report) . (Read: Apple Updates Portfolio Prior to Streaming Service Launch)
Exxon Mobil Corporation (XOM - Free Report) and TOTAL SA have reached an agreement related to increased gas exports from Papua New Guinea (PNG).
Per the plan, the capacity of Zacks Rank #3 ExxonMobil-operated PNG liquefied natural gas (LNG) plant will be increased to around 16 million tons per annum (mtpa) from its current capacity of 6.9 mtpa. According to analysts, the move will enable the company to compete with Australia’s biggest LNG projects.
The cost of the expansion is valued at about $13 billion, lower than the initial cost projection of $19.5 billion. The cost per ton is less than 50% from Chevron Corp’s (CVX - Free Report) Gorgon LNG plant in Australia.
The expansion will include the addition of three new LNG trains with a capacity of 2.7 mtpa each on the existing PNG LNG plant site. Two of these trains will be supported by gas from the Elk-Antelope fields, which is managed by TOTAL. (Read: ExxonMobil to Increase Export From PNG LNG Plant)
Boeing recently won a $327 million contract to upgrade the P-8A aircraft. The contract was awarded by the Naval Air Systems Command, Patuxent River, Maryland.
Per the terms of the deal, the aerospace giant will develop, integrate and test Increment 3 Block capabilities into the P-8A aircraft for the Navy and the government of Australia. Majority of the work related to the deal will be performed in Puget Sound, WA. The entire task related to the deal is expected to be completed by March 2024.
Boeing will utilize fiscal 2019 research, development, test and evaluation (Navy) funds and Cooperative Engagement Agreement funds for completing the task. The stock has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Goldman Sachs (GS - Free Report) , through its subsidiary Goldman Sachs Asset Management ("GSAM"), has agreed to acquire Standard & Poor's Investment Advisory Services LLC ("SPIAS"), a wholly owned subsidiary of S&P Global (SPGI - Free Report) . The deal is expected to close in the first half of 2019.
SPIAS manages portfolios using Exchange Traded Funds (“ETFs”) and mutual funds, as well as equity portfolios produced employing a rules-based investment process. It is a provider of non-discretionary advisory services to institutional clients on a global level.
As of Dec 31, 2018, it advised on more than $33 billion in assets across multi-asset, equity, and fixed income strategies.
Zacks Rank #4 (Sell) Goldman’s ETFs sales are likely to get a boost from this acquisition, which will expand the unit’s multi-asset offerings and rules-based equity strategies. The expansion is in sync with the growing demands of customers. (Read: Goldman Sachs to Acquire S&P's Investment Advisory Services)
Pfizer, Inc. (PFE - Free Report) and partner Merck KGaA announced the discontinuation of a late-stage study evaluating a combination of its PD-L1 inhibitor, Bavencio and its new PARP inhibitor, Talzenna (talazoparib) for first-line ovarian cancer. Pfizer has a Zacks Rank #4.
The phase III JAVELIN Ovarian PARP 100 study (n=998) evaluated Bavencio (avelumab) + chemotherapy followed by a maintenance treatment of avelumab + Talzenna versus an active comparator for previously untreated advanced ovarian cancer.
The companies said several factors led to the decision to end the JAVELIN Ovarian PARP 100 study, which did not include safety reasons. First, the degree of benefit observed with avelumab in frontline ovarian cancer in the JAVELIN Ovarian 100 study did not support continuation of the JAVELIN Ovarian PARP 100 study, the companies said or for that matter evaluating an immunotherapy in ovarian cancer itself.
Also, the approval of AstraZeneca/Merck’s PARP inhibitor, Lynparza in the first-line maintenance setting for ovarian cancer in December last year has raised competitive pressure in the PARP inhibitor market. (Read: Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study)
JPMorgan Chase (JPM - Free Report) has started offering low-fee checkless accounts. The new account, called Secure, does not require any minimum balance and has access to the company’s mobile app, branches and ATMs for $4.95 a month. The news was first reported by Reuters. JPMorgan has a Zacks Rank #4.
These accounts are no-overdraft accounts but come with debit cards, digital payments and free check cashing. Moreover, these accounts charge $60 annually, which is significantly below the charge of $200-$500 per annum at check cashing and money order services. (Read: JPMorgan Offers Checkless Accounts for Low-Income Customers)
Performance of the Top 10 Dow Companies
The table given below shows the price movements of the 10 largest components of the Dow, which is a price-weighted index, over the last five days and during the last six months. Over the last five trading days, the Dow has gained 0.6%.
Next Week’s Outlook
Boeing’s woes are far from over and will continue to trouble the Dow for some time to come. However, the stock’s fundamentals are in place and such volatility could be short term at best. Further, investors will be relieved that a rate hike has been more or less been ruled out for the year.
However, concerns over trade negotiations continue to linger and will likely keep investors guessing next week. If crucial economic data, such as upcoming GDP numbers are encouraging, stocks could receive the impetus required for steady gains in the days ahead.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>